Mydecine Innovations Group Inc. (MYCO.NE) Research

Mydecine Innovations Group Inc. is a biotechnology and life sciences enterprise dedicated to advancing and commercializing therapies for a range of mental health conditions. The company specializes in developing treatments for specific populations, including veterans, emergency medical service providers, frontline workers, and individuals affected by post-traumatic stress disorder. It also operates Mindleap, an online telehealth platform offering mental wellness services and support for psychedelic integration, including aftercare. Furthermore, Mydecine engages in drug discovery, developing nature-derived psychedelic-assisted therapeutics, novel compounds, specific therapy protocols, and unique drug delivery systems. The company also manages a hemp cultivation facility in Pottus, Texas. Strategic collaborations include alliances with Leiden University Medical Center, Royal Ottawa Mental Health Centre, and LeadGen Labs for psychedelic drug development, as well as Applied Pharmaceutical Innovation for drug development and clinical trial programs. Founded in 2013, the company, originally known as NewLeaf Brands Inc., rebranded as Mydecine Innovations Group Inc. in June 2020 and is headquartered in Vancouver, Canada.

Market snapshot

Symbol
MYCO.NE
Price
$0.35
Day change
0.00%
Market cap
$21.4M
P/E ratio
9.80x
52-week range
0.35-0.35
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Avant Brands Inc. (AVNT.TO)
  • Ayurcann Holdings Corp. (AYUR.CN)
  • Blueberries Medical Corp. (BBM.CN)
  • Christina Lake Cannabis Corp. (CLC.CN)
  • CLS Holdings USA, Inc. (CLSH.CN)
  • Crescita Therapeutics Inc. (CTX.TO)
  • Delivra Health Brands Inc. (DHB.V)
  • Lobe Sciences Ltd. (LOBE.CN)

Open Mydecine Innovations Group Inc. (MYCO.NE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.